Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 7/20 | 0.48 |
| ▸ | EGFR | P00533 | 4/20 | 0.47 |
| ▸ | KMT5A | Q9NQR1 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 3/20 | 0.43 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20303958 | 0.89 | EHMT2 (0.48) | EHMT2EGFRKMT5AENPP1ACHE | |
| SCHEMBL20347593 | 0.83 | EHMT2 (0.52) | EHMT2EGFRKMT5AKDRERBB2 | |
| SCHEMBL20303783 | 0.80 | SPIN1 (0.59) | EHMT2 | |
| SCHEMBL20303911 | 0.80 | SPIN1 (0.59) | EHMT2 | |
| Formic Acid SCHEMBL30509144 | 0.79 | EHMT2 (0.49) | EHMT2EGFRKMT5AKDRACHE | |
| Formic Acid SCHEMBL20303885 | 0.79 | EHMT2 (0.49) | EHMT2EGFRKMT5AKDRACHE | |
| SCHEMBL20303932 | 0.78 | SPIN1 (0.59) | EHMT2 | |
| SCHEMBL20336777 | 0.77 | EGFR (0.53) | EHMT2EGFRKDRERBB2 | |
| SCHEMBL29385684 | 0.77 | EGFR (0.53) | EHMT2EGFRKDRERBB2 | |
| SCHEMBL20755177 | 0.76 | EHMT2 (0.59) | EHMT2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4063358-B1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2024-05-22 | — | — | EP | disclosed |
| US-11713299-B2 | Histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713299-B2 | Histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713299-B2 | Histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| EP-4063358-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | Global Blood Therapeutics, Inc. (US) | 2022-09-28 | — | — | EP | disclosed |
| EP-3558971-B1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2022-02-23 | — | — | EP | disclosed |
| US-20210107876-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2021-04-15 | — | — | US | disclosed |
| US-20210107876-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2021-04-15 | — | — | US | disclosed |
| US-10829452-B2 | Histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-10829452-B2 | Histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| EP-3558971-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | Global Blood Therapeutics, Inc. (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20180186745-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2018-07-05 | — | — | US | disclosed |
| US-20180186745-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2018-07-05 | — | — | US | disclosed |
| US-20180186745-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2018-07-05 | — | — | US | disclosed |
| WO-2018119208-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186745-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, EZH2 | EHMT2 2/4885EGFR 4854/4885KMT5A 31/4885 |
| US-10829452-B2 | Histone methyltransferase inhibitors | EHMT1, DOT1L, EHMT2 | EHMT2 3/4885EGFR 4205/4885KMT5A 43/4885 |
| US-20210107876-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, EZH2 | EHMT2 2/4885EGFR 4854/4885KMT5A 31/4885 |
| US-11713299-B2 | Histone methyltransferase inhibitors | EHMT1, DOT1L, EHMT2 | EHMT2 3/4885EGFR 4209/4885KMT5A 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.